TMCnet News

Research and Markets: Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
[June 12, 2014]

Research and Markets: Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/hw23pr/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Drug profiles/recors featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.



The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Companies Mentioned:

  • Bristol-Myers Squibb Company
  • AstraZeneca
  • MedImmune
  • Isis Pharmaceuticals
  • Gilead Sciences
  • Daiichi Sankyo Company
  • Merck & Co
  • CardioVascular BioTherapeutics
  • Bayer AG
  • AnGes MG
  • Pluristem Therapeutics
  • AngioDesign
  • ViroMed
  • Miltenyi Biotec
  • Multi Gene Vascular Systems
  • Lonestar Heart
  • Biscayne Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/hw23pr/coronary_artery


[ Back To TMCnet.com's Homepage ]